<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459316</url>
  </required_header>
  <id_info>
    <org_study_id>P1065</org_study_id>
    <secondary_id>10396</secondary_id>
    <secondary_id>IMPAACT P1065</secondary_id>
    <secondary_id>PACTG P1065</secondary_id>
    <nct_id>NCT00459316</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth</brief_title>
  <official_title>Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in HIV-Infected Children and Youth And Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Bacterial meningitis infection is common in youth 2 to 24 years of age in the United States.
      This disease can be treated by antibiotics, but mortality rates associated with meningitis of
      up to 53% have been estimated. Vaccination against meningitis may be effective in preventing
      this disease, especially for HIV-infected youth who have weakened immune systems. The purpose
      of this study was to determine the safety of and immune response to a preventive meningitis
      vaccine in HIV-infected youth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States, youth 2 to 24 years of age are at high risk for bacterial meningitis
      infection. Despite antibiotic treatment, the mortality rate for meningitis and sepsis can
      reach as high as 53% caused by Neisseria meningitidis. This rate could be higher in
      immunocompromised individuals, such as those infected with HIV. To prevent infection,
      vaccination against meningitis is recommended by the CDC at ages 11, 15, and 18. The
      quadrivalent meningococcal conjugate vaccine (MCV4) is a vaccine that has been observed to
      elicit an appropriate immune response to N. meningitidis and was approved by the FDA in
      January 2005. However, to date, no studies have been done to determine the safety and
      immunogenicity of this vaccine in HIV-infected individuals. The purpose of this study was to
      determine the safety and immunogenicity of MCV4 in HIV-infected youth 2 to 24 years of age.

      The study was originally designed for participants to be followed for 72 weeks. Participants
      were enrolled in three groups by age and CD4% as follows:

      Group 1: Age 11 to 24 years, CD4% of 15% or higher. Enrollment was further stratified by
      CD4%: 15% to &lt;25%, and &gt;= 25%.

      Group 2: Age 11 to 24 years, CD4% &lt; 15%.

      Group 3: Age 2 to 10 years, CD4% of 25% or higher.

      At study entry, all study participants received one injection of MCV4 (Step 1). Participants
      were observed for 30 minutes post-injection to monitor for adverse events. A clinic visit was
      required 24 hours post-injection if the participant reported adverse events. At Week 24,
      participants in Group 1 who did not experience any disqualifying adverse events after the
      first injection were randomly assigned to receive a second injection of MCV4 or no further
      injections. Group 2, and Group 3 participants who had no disqualifying adverse events after
      the first injection received a second injection of MCV4 at Week 24 (Step 2).

      There were five study visits in Steps 1 and 2; they occurred at study entry and at Weeks 4,
      24, 28, and 72. At these visits, a physical exam, assessment of HIV-related symptoms, and
      blood collection occurred. In addition, study participants were contacted by telephone at
      Days 3 and 7 and Weeks 1, 6, and 25 after the first vaccination. Participants in Groups 1B
      and 2 who received a second injection were contacted by telephone at Weeks 30 and 48.

      As of November 2010, due to data from this study (P1065) and recommendations from the
      Advisory Committee for Immunization Practices (ACIP) of the Center for Disease Control (CDC),
      eligible participants in Groups 1 (1A and 1B) and 3 of P1065 received a booster dose of MCV4
      at approximately 3.5 years (+/- 6 months) after the initial MCV4 vaccination. Participants
      were then observed for 30 minutes post-injection to monitor for adverse events. Participants
      were also observed at Week 1 for vaccine adverse reactions.

      This portion of the study (Step 3) lasted an additional 24 weeks. There were 4 study visits;
      they occurred at entry, at Days 7-8, and at Weeks 4 and 24. At these visits, a physical exam,
      assessment of HIV-related symptoms, and blood collection occurred. The purpose of this
      follow-up study was to determine the safety and immunogenicity of a MCV4 booster dose in
      HIV-infected participants who have previously received one or two MCV4 vaccinations on this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses of MCV-4.</measure>
    <time_frame>Study entry and Week 28</time_frame>
    <description>Serum bactericidal antibody titers were measured at study entry and Week 28 for each of the four serogroups in the MCV-4 vaccine. Response was defined as a 4-fold or greater increase from entry at Week 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Short-term Immunogenicity, Defined as Number of Seroconverters at Week 4 (Those With at Least a 4-fold Rise in Meningococcal Serum Bactericidal Titers From Baseline)</measure>
    <time_frame>At Study entry, Week 4</time_frame>
    <description>Serum bactericidal antibody titers were measured at study entry and Week 4 for each of the four serogroups in the MCV-4 vaccine. Response (seroconversion) was defined as a 4-fold or greater increase from entry at Week 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term Immunogenicity, as Assessed by Number of Participants With Protective Levels of Antibody at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Protective levels of antibody are titers â‰¥1:128.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Adverse Events Within 42 Days Following Dose 1 of the Vaccine.</measure>
    <time_frame>From administration of Dose 1 at week 0 to 42 days post-vaccination</time_frame>
    <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Dose 2 of the Vaccine.</measure>
    <time_frame>From administration of Dose 2 at week 24 to 6 weeks post-vaccination</time_frame>
    <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immunogenicity at Step 3 Entry</measure>
    <time_frame>At 3.5 years (Step 3 entry)</time_frame>
    <description>Immunogenicity was assessed for each serogroup by the number of participants with protective antibody levels (titers greater than or equal to 1:128)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 4-fold Memory Response in Step 3</measure>
    <time_frame>Step 3 entry and Week 1 post-booster vaccine</time_frame>
    <description>Defined for each serogroup as a four-fold rise in antibody titers between booster dose (week 0) and week 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Seropositive Memory Response (in Step 3)</measure>
    <time_frame>Step 3 entry and Week 1 post-booster vaccine</time_frame>
    <description>Seropositive memory response was defined for each serogroup by having protective antibody levels (titer &gt;= 1:128) on Day 0 or change from seronegative to seropositive between booster dose (Day 0) and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Primary Response (in Step 3)</measure>
    <time_frame>Step 3 entry and Week 4 post-booster vaccine</time_frame>
    <description>Primary response was defined for each serogroup as a four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; OR a change from seronegative on day 0 to seropositive on day 28, but not between day 0 and day 7. Note: a primary response can only occur in the absence of any memory response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immunogenicity at Step 3 Weeks 4 and 24</measure>
    <time_frame>At Step 3 Weeks 4 and 24 post-booster vaccine</time_frame>
    <description>Immunogenicity was assessed by the number of participants with protective levels of antibody (titers greater than or equal to 1:128)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenic Response to Serogroup C in Group 2</measure>
    <time_frame>At Weeks 4, 28, and 72</time_frame>
    <description>Immunogenic response as assessed by number of participants with protective antibody titers (&gt;= 1:128) to serogroup C in Group 2 (entry CD4%&lt;15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protective Antibody Titers for Serogroup C at Step 3 Entry</measure>
    <time_frame>At 3.5 years</time_frame>
    <description>Number of participants with protective antibody titers (rSBA&gt;=1:128) for serogroup C by treatment arm (1 vs. 2 doses) of Group 1 (entry CD4% &gt;= 15) at Step 3 entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Memory for Serogroup C by Treatment Arm (1 vs. 2 Doses)</measure>
    <time_frame>At Week 1 post-booster vaccination</time_frame>
    <description>Evidence of immunologic memory according to each of the following definitions:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Memory or Primary Response for Serogroup C by Treatment Arm</measure>
    <time_frame>At Week 4 post-booster vaccination</time_frame>
    <description>Immunologic Memory defined as:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.
Primary Response defined as:
A four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; or
A change from titer &lt;1:128 on day 0 to titer â‰¥1:128on day 28, but not between day 0 and day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, as Assessed by Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Step 3 Dose of the Vaccine.</measure>
    <time_frame>From administration of vaccination at Step 3 entry through 6 weeks post-vaccination</time_frame>
    <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>HIV Infections</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants â‰¤11 to &lt;25 years of age with CD4% at screening â‰¥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants â‰¤11 to &lt;25 years of age with CD4% at screening &lt;15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants &gt;=2 to &lt;11 years of age with CD4% at screening â‰¥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent meningococcal conjugate vaccine</intervention_name>
    <description>MCV4 vaccine (4 Âµg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 Âµg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>MCV4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Steps 1, 2, and 3:

          -  HIV-infected

          -  Age greater than or equal to 2 and less than 25 years (Steps 1 and 2 only)

          -  CD4% documented within 120 days of study entry

          -  Participants on antiretroviral therapy (ART) must have been on stable ART regimen for
             at least 90 days prior to study entry

          -  Able and willing to complete all study immunizations and evaluations

          -  Parent or guardian willing to provide informed consent, if applicable

          -  Participants and/or their partners who are sexually active had to agree to use at
             least one of the following methods of contraception as long as they are on the study:
             hormonal birth control drugs (oral, injectable or transdermal); male or female condoms
             with or without a spermicide; diaphragm/cervical cap with spermicide; intrauterine
             device (IUD)

        Inclusion Criteria specific to Step 3:

          -  Participants must have been enrolled in Groups 1 or 3 of previous versions of P1065

          -  Participants did not have to be less than 25 years of age

          -  Participants must have had serology data from Weeks 0, 4, and 28 from their previous
             participation in P1065

          -  Participants must have been within 3.5 years +/- 6 months from the first MCV4 dose
             received in a previous version of P1065

        Exclusion Criteria for Step 1:

          -  Any nonstudy vaccine on study entry day

          -  Any inactive vaccine within 2 weeks prior to study entry

          -  Plans to receive any vaccine 2 weeks after the first injection

          -  Receipt of any live nonstudy vaccine within 4 weeks prior to study entry

          -  Meningococcal conjugate vaccine at any time prior to study entry

          -  Meningococcal polysaccharide vaccine within 2 years prior to study entry

          -  Known hypersensitivity to any component of the MCV4 vaccine, including diphtheria
             toxoid

          -  Known hypersensitivity to dry natural rubber latex

          -  Life-threatening reaction after previous administration of a vaccine containing
             similar components

          -  Family history or personal history of Guillain-Barre Syndrome (GBS)

          -  Clinically significant diseases that, in the investigator's opinion, would interfere
             with the study

          -  Current immunomodulatory therapy, including IL-2, any interferon product, GM-CSF, or
             thalidomide. Participants taking G-CSF or erythropoietin were not excluded.

          -  Current immunosuppressive therapy, including equivalent of 1 mg/kg/per day or more of
             prednisone 2 weeks prior to study entry OR planned corticosteroid therapy lasting 2
             weeks or longer. Participants using nonsteroidal anti-inflammatory agents and inhaled
             corticosteroids are not excluded.

          -  Cancer within 12 weeks of study entry

          -  Cancer treatment currently or within 12 weeks of study entry

          -  Loss of strength in lower extremity within 24 weeks prior to study entry

          -  Bleeding disorder or anticoagulant therapy prior to study entry

          -  Absence of ankle and patellar deep tendon reflexes (DTRs) (all four)

          -  Recent receipt of IGIV or any blood or immunoglobulin product (except washed blood
             cells). More information about this criterion can be found in the protocol.

          -  Other acute or chronic medical or surgical conditions or contraindications that, in
             the opinion of the investigator, might have interfered with the study

          -  Any new and unresolved Grade 3 or higher laboratory toxicity within 120 days prior to
             study entry

          -  Any new and unresolved Grade 3 or higher clinical toxicity within 120 days prior to
             study entry

          -  Pregnancy or breastfeeding

        Exclusion Criteria for Step 2:

          -  New occurrence or awareness of GBS in the participant or participant's family since
             study entry

          -  Loss of strength in lower extremity or extremities since first vaccination

          -  Absence of ankle and patellar DTRs (all four)

          -  New diagnosis of active cancer, or chemotherapy treatment of an established cancer
             diagnosis since study entry

          -  Any Grade 4 toxicity since last vaccination. Participants who experience toxicities
             unrelated to the vaccine are not excluded.

          -  Change in ART in the 90 days prior to second vaccination

          -  Certain Grade 3 toxicities. More information on this criterion can be found in the
             protocol.

          -  Treatment with immunosuppressive or immunomodulation therapy (other than
             corticosteroids) within 60 days of planned second vaccination

          -  Severe allergic reaction requiring medical intervention within 24 hours of the first
             vaccination

          -  New diagnosis of any coagulation disorder that would contraindicate intramuscular
             injection

          -  Toxicity from first vaccination. More information on this criterion can be found in
             the protocol.

          -  Any new diseases that the investigator judges to be clinically significant OR
             clinically significant findings since the first vaccination that, in the opinion of
             the investigator, would interfere with the study

          -  Any new clinical Grade 3 or higher toxicity that has not resolved within 2 weeks prior
             to planned second vaccination

          -  Pregnancy or breastfeeding. Pregnant or breastfeeding participants were to be followed
             to pregnancy outcome.

        Exclusion Criteria for Step 3:

          -  Receipt of any dose of non-study meningococcal vaccine since initial enrollment into
             P1065

          -  New occurrence or new awareness of GBS in the participant or participant's family
             since the last P1065 study visit

          -  Loss of strength in lower extremity or extremities since the last MCV4 vaccination

          -  Absence of ankle and patellar Deep Tendon Reflexes (DTRs) (all 4)

          -  New diagnosis of an active malignancy, or chemotherapy treatment of an established
             diagnosis since the last P1065 study visit

          -  New diagnosis or suspected disease of the immune system since the last P1065 study
             visit

          -  Participant or legal guardian refuses further vaccine

          -  Participant requiring treatment with medications that were disallowed while on this
             study (see protocol)

          -  Grade 3 or higher toxicities (for example, Grade 3 seizure or allergic reaction)
             secondary to receipt of vaccine in previous version of P1065 meriting vaccine
             discontinuation, as determined by the IMPAACT P1065 Protocol Team and the site
             principal investigator

          -  Current immunomodulatory therapy, including IL-2, any interferon product, GM-CSF, or
             thalidomide [Note: G-CSF and erythropoietin are allowed]

          -  Current immunosuppressive therapy, including the equivalent of greater than or equal
             to 1 mg/kg/per day of prednisone in the 2 weeks preceding study entry

          -  Participants for whom long-term corticosteroid therapy (greater than or equal to 2
             weeks) was anticipated were excluded [Note: non-steroidal anti-inflammatory agents and
             inhaled, intranasal and topical corticosteroids were allowed]

          -  A severe allergic reaction (e.g., swelling of the mouth and throat, difficulty
             breathing, hypotension, or shock) that required medical intervention, occurring within
             24 hours of the first vaccine and potentially attributable to that first vaccine

          -  New diagnosis of any coagulation disorder that would contraindicate IM injections
             since the last P1065 study visit

          -  Breastfeeding

          -  Any new diseases which the investigators judged to be clinically significant (other
             than HIV infection) or clinically significant findings since enrollment into P1065
             that, in the investigators' opinion, would have compromise the outcome of this study

          -  Any new greater than or equal to grade 3 clinical toxicity that is not related to
             vaccine and had not resolved within 2 weeks before entry into Step 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George K. Siberry, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric, Adolescent, and Maternal AIDS (PAMA) Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Lujan-Zilbermann, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases, Department of Pediatrics, University of South Florida College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hosp. Long Beach CA NICHD CRS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles NICHD CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, UC San Diego CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of California San Francisco NICHD CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Medical Ctr. NICHD CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Med. Ctr. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Florida Jacksonville NICHD CRS</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Perinatal HIV Clinical Trials Unit CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF - Tampa NICHD CRS</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Cook County Hosp. Chicago NICHD CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (LCH) CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ. New Orleans NICHD CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Maryland Baltimore NICHD CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. of Boston NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Ped. HIV Program NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WNE Maternal Pediatric Adolescent AIDS CRS</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan NICHD CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Ny Nichd Crs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hosp. NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia IMPAACT CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strong Memorial Hospital Rochester NY NICHD CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hosp. of Philadelphia IMPAACT CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico Pediatric HIV/AIDS Research Program CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Campos-Outcalt D. Meningococcal vaccine: New product, new recommendations. J Fam Pract. 2005 Apr;54(4):324-6. Review.</citation>
    <PMID>15833222</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Update: Guillain-BarrÃ© syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006 Oct 20;55(41):1120-4. Erratum in: MMWR Morb Mortal Wkly Rep. 2006 Nov 3;55(43):1177.</citation>
    <PMID>17060898</PMID>
  </reference>
  <reference>
    <citation>Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13.</citation>
    <PMID>16203934</PMID>
  </reference>
  <reference>
    <citation>Mehlhorn AJ, Balcer HE, Sucher BJ. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine. Ann Pharmacother. 2006 Apr;40(4):666-73. Epub 2006 Mar 7. Review.</citation>
    <PMID>16595570</PMID>
  </reference>
  <reference>
    <citation>Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, KÃ¤yhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003 Oct 1;21(27-30):4437-47.</citation>
    <PMID>14505927</PMID>
  </reference>
  <reference>
    <citation>Pearson IC, Baker R, Sullivan AK, Nelson MR, Gazzard BG. Meningococcal infection in patients with the human immunodeficiency virus and acquired immunodeficiency syndrome. Int J STD AIDS. 2001 Jun;12(6):410-1.</citation>
    <PMID>11368827</PMID>
  </reference>
  <results_reference>
    <citation>Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.</citation>
    <PMID>20431379</PMID>
  </results_reference>
  <results_reference>
    <citation>Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL, Jean-Philippe P, Fenton T, Siberry GK; IMPAACT P1065 Protocol Team. Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCÎ³ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth. Clin Vaccine Immunol. 2013 Jun;20(6):900-6. doi: 10.1128/CVI.00042-13. Epub 2013 Apr 17.</citation>
    <PMID>23595505</PMID>
  </results_reference>
  <results_reference>
    <citation>Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.</citation>
    <PMID>22622049</PMID>
  </results_reference>
  <results_reference>
    <citation>Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.</citation>
    <PMID>21987006</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2007</study_first_submitted>
  <study_first_submitted_qc>April 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>April 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2014</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: CD4%â‰¥15, Age â‰¤11 to &lt;25</title>
          <description>Participants â‰¤11 to &lt;25 years of age with CD4% at screening â‰¥15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible/randomized receiving Quadrivalent meningococcal conjugate vaccine at week 24, and 3 years.
Quadrivalent meningococcal conjugate vaccine: MCV4 vaccine (4 Âµg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 Âµg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than two times for each participant, depending on adverse reactions.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: CD4%&lt;15, Age â‰¤11 to &lt;25</title>
          <description>Participants â‰¤11 to &lt;25 years of age with CD4% at screening &lt;15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24.
Quadrivalent meningococcal conjugate vaccine: MCV4 vaccine (4 Âµg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 Âµg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than two times for each participant, depending on adverse reactions.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Age â‰¥2 to &lt;11, CD4%â‰¥25</title>
          <description>Participants â‰¥2 to &lt;11 years of age with CD4% at screening â‰¥ 25%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24, and 3 years.
Quadrivalent meningococcal conjugate vaccine: MCV4 vaccine (4 Âµg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 Âµg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than two times for each participant, depending on adverse reactions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Steps 1 &amp; 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other eligibility failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to adhere to regulations</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Step 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152">Not all participants from Steps 1/2 were eligible for Step 3</participants>
                <participants group_id="P2" count="0">Group 2 participants were not eligible for Step 3</participants>
                <participants group_id="P3" count="40">Not all participants from Steps 1/2 were eligible for Step 3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who started study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (15&lt;CD4%&lt;25)</title>
          <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%&lt;25</description>
        </group>
        <group group_id="B2">
          <title>Group 1 (CD4%â‰¥25)</title>
          <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
        </group>
        <group group_id="B3">
          <title>Group 2</title>
          <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
        </group>
        <group group_id="B4">
          <title>Group 3</title>
          <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="59"/>
            <count group_id="B5" value="378"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="B2" value="16" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="B3" value="20" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="B4" value="6" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="B5" value="16" lower_limit="2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than One race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening CD4%</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" lower_limit="14.0" upper_limit="24.9"/>
                    <measurement group_id="B2" value="33.0" lower_limit="25.0" upper_limit="53.1"/>
                    <measurement group_id="B3" value="8.5" lower_limit="1.0" upper_limit="14.0"/>
                    <measurement group_id="B4" value="36.0" lower_limit="25.0" upper_limit="56.0"/>
                    <measurement group_id="B5" value="27.9" lower_limit="1.0" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Entry plasma HIV RNA viral load, copies/mL</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥ 400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CDC Classification at Study Entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antiretroviral (ARV) Treatment at Entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HAART with PI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAART with NNRTI (no PI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other ARV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No ARV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses of MCV-4.</title>
        <description>Serum bactericidal antibody titers were measured at study entry and Week 28 for each of the four serogroups in the MCV-4 vaccine. Response was defined as a 4-fold or greater increase from entry at Week 28.</description>
        <time_frame>Study entry and Week 28</time_frame>
        <population>This outcome only includes participants who received 2 doses and had antibody data from both entry and Week 28.The number of participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 are respectively:
serogroup A: 49, 63, 20, 49 serogroup C: 47, 65, 18, 49 serogroup W-135: 47, 66, 19, 49 serogroup Y: 49, 66, 19, 49</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (15&lt;CD4%&lt;25)</title>
            <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (CD4%â‰¥25)</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
          </group>
          <group group_id="O4">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses of MCV-4.</title>
          <description>Serum bactericidal antibody titers were measured at study entry and Week 28 for each of the four serogroups in the MCV-4 vaccine. Response was defined as a 4-fold or greater increase from entry at Week 28.</description>
          <population>This outcome only includes participants who received 2 doses and had antibody data from both entry and Week 28.The number of participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 are respectively:
serogroup A: 49, 63, 20, 49 serogroup C: 47, 65, 18, 49 serogroup W-135: 47, 66, 19, 49 serogroup Y: 49, 66, 19, 49</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 28 reponders, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="0.87" upper_limit="0.99"/>
                    <measurement group_id="O2" value="60" lower_limit="0.40" upper_limit="0.69"/>
                    <measurement group_id="O3" value="8" lower_limit="0.19" upper_limit="0.64"/>
                    <measurement group_id="O4" value="43" lower_limit="0.75" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 reponders, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="0.44" upper_limit="0.74"/>
                    <measurement group_id="O2" value="49" lower_limit="0.63" upper_limit="0.85"/>
                    <measurement group_id="O3" value="1" lower_limit="0.001" upper_limit="0.27"/>
                    <measurement group_id="O4" value="39" lower_limit="0.66" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 reponders, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="0.50" upper_limit="0.78"/>
                    <measurement group_id="O2" value="61" lower_limit="0.70" upper_limit="0.90"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.18"/>
                    <measurement group_id="O4" value="49" lower_limit="0.93" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 reponders, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="0.62" upper_limit="0.88"/>
                    <measurement group_id="O2" value="54" lower_limit="0.83" upper_limit="0.97"/>
                    <measurement group_id="O3" value="1" lower_limit="0.001" upper_limit="0.25"/>
                    <measurement group_id="O4" value="41" lower_limit="0.70" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Short-term Immunogenicity, Defined as Number of Seroconverters at Week 4 (Those With at Least a 4-fold Rise in Meningococcal Serum Bactericidal Titers From Baseline)</title>
        <description>Serum bactericidal antibody titers were measured at study entry and Week 4 for each of the four serogroups in the MCV-4 vaccine. Response (seroconversion) was defined as a 4-fold or greater increase from entry at Week 4.</description>
        <time_frame>At Study entry, Week 4</time_frame>
        <population>This outcome only includes participants who had antibody data from both entry and Week 4.The number of participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 respectively are:
serogroup A are 93, 129, 20, 49 serogroup C are 90, 130, 18, 49 serogroup W-135 are 91, 131, 19, 49 serogroup Y are 93, 131, 20, 49</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (15&lt;CD4%&lt;25)</title>
            <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (CD4%â‰¥25)</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
          </group>
          <group group_id="O4">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4%â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Short-term Immunogenicity, Defined as Number of Seroconverters at Week 4 (Those With at Least a 4-fold Rise in Meningococcal Serum Bactericidal Titers From Baseline)</title>
          <description>Serum bactericidal antibody titers were measured at study entry and Week 4 for each of the four serogroups in the MCV-4 vaccine. Response (seroconversion) was defined as a 4-fold or greater increase from entry at Week 4.</description>
          <population>This outcome only includes participants who had antibody data from both entry and Week 4.The number of participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 respectively are:
serogroup A are 93, 129, 20, 49 serogroup C are 90, 130, 18, 49 serogroup W-135 are 91, 131, 19, 49 serogroup Y are 93, 131, 20, 49</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Seroconverters, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Seroconverters, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Seroconverters, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Seroconverters, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Long-term Immunogenicity, as Assessed by Number of Participants With Protective Levels of Antibody at Week 72</title>
        <description>Protective levels of antibody are titers â‰¥1:128.</description>
        <time_frame>Week 72</time_frame>
        <population>Participants with antibody data at Week 72. The number of Participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 respectively are:
serogroup A are 82, 108, 18, 44 serogroup C are 78, 110, 16, 44 serogroup W-135 are 80, 110, 17, 44 serogroup Y are 82, 110, 18, 44</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (15&lt;CD4%&lt;25)</title>
            <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (CD4%â‰¥25)</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
          </group>
          <group group_id="O4">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4%â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Immunogenicity, as Assessed by Number of Participants With Protective Levels of Antibody at Week 72</title>
          <description>Protective levels of antibody are titers â‰¥1:128.</description>
          <population>Participants with antibody data at Week 72. The number of Participants analyzed for Group 1 (15&lt;CD4%&lt;25), Group 1 (CD4%â‰¥25), Group 2, Group 3 respectively are:
serogroup A are 82, 108, 18, 44 serogroup C are 78, 110, 16, 44 serogroup W-135 are 80, 110, 17, 44 serogroup Y are 82, 110, 18, 44</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 72 Responders, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 Responders, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 Responders, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72 Responders, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 or Higher Adverse Events Within 42 Days Following Dose 1 of the Vaccine.</title>
        <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
        <time_frame>From administration of Dose 1 at week 0 to 42 days post-vaccination</time_frame>
        <population>All participants who received Dose 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (15&lt;CD4%&lt;25)</title>
            <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (CD4%â‰¥25)</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
          </group>
          <group group_id="O4">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4%â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Adverse Events Within 42 Days Following Dose 1 of the Vaccine.</title>
          <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
          <population>All participants who received Dose 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there would be no difference between CD4% strata.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>Two-sided p-value &lt;0.05 was specified as statistically significant a priori. There were no adjustments for multiple outcomes.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Dose 2 of the Vaccine.</title>
        <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
        <time_frame>From administration of Dose 2 at week 24 to 6 weeks post-vaccination</time_frame>
        <population>All participants who entered Step 2</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (15&lt;CD4%&lt;25)</title>
            <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
          </group>
          <group group_id="O2">
            <title>Group 1 (CD4%â‰¥25)</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
          </group>
          <group group_id="O4">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Dose 2 of the Vaccine.</title>
          <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
          <population>All participants who entered Step 2</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there were no differences between CD4% strata.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>Two sided-p-value &lt;0.05 was specified as statistically significant a priori. No adjustment for multiple primary outcomes was made.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immunogenicity at Step 3 Entry</title>
        <description>Immunogenicity was assessed for each serogroup by the number of participants with protective antibody levels (titers greater than or equal to 1:128)</description>
        <time_frame>At 3.5 years (Step 3 entry)</time_frame>
        <population>All participants who had antibody data for Step 3 Week 0</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immunogenicity at Step 3 Entry</title>
          <description>Immunogenicity was assessed for each serogroup by the number of participants with protective antibody levels (titers greater than or equal to 1:128)</description>
          <population>All participants who had antibody data for Step 3 Week 0</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immunogenicity, Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit=".52" upper_limit=".75"/>
                    <measurement group_id="O2" value="48" lower_limit=".51" upper_limit=".73"/>
                    <measurement group_id="O3" value="34" lower_limit=".73" upper_limit=".96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunogenicity, Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit=".16" upper_limit=".38"/>
                    <measurement group_id="O2" value="20" lower_limit=".17" upper_limit=".37"/>
                    <measurement group_id="O3" value="9" lower_limit=".11" upper_limit=".39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunogenicity, Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit=".30" upper_limit=".53"/>
                    <measurement group_id="O2" value="35" lower_limit=".34" upper_limit=".57"/>
                    <measurement group_id="O3" value="23" lower_limit=".42" upper_limit=".74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunogenicity, Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit=".41" upper_limit=".65"/>
                    <measurement group_id="O2" value="33" lower_limit=".32" upper_limit=".55"/>
                    <measurement group_id="O3" value="24" lower_limit=".45" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 4-fold Memory Response in Step 3</title>
        <description>Defined for each serogroup as a four-fold rise in antibody titers between booster dose (week 0) and week 1.</description>
        <time_frame>Step 3 entry and Week 1 post-booster vaccine</time_frame>
        <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 4-fold Memory Response in Step 3</title>
          <description>Defined for each serogroup as a four-fold rise in antibody titers between booster dose (week 0) and week 1.</description>
          <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4-fold memory responders, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="0.62" upper_limit="0.84"/>
                    <measurement group_id="O2" value="49" lower_limit="0.61" upper_limit="0.83"/>
                    <measurement group_id="O3" value="33" lower_limit="0.78" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-fold memory responders, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="0.65" upper_limit="0.86"/>
                    <measurement group_id="O2" value="50" lower_limit="0.63" upper_limit="0.84"/>
                    <measurement group_id="O3" value="34" lower_limit="0.81" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-fold memory responders, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="0.76" upper_limit="0.93"/>
                    <measurement group_id="O2" value="55" lower_limit="0.73" upper_limit="0.92"/>
                    <measurement group_id="O3" value="33" lower_limit="0.78" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-fold memory responders, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="0.62" upper_limit="0.84"/>
                    <measurement group_id="O2" value="51" lower_limit="0.67" upper_limit="0.88"/>
                    <measurement group_id="O3" value="33" lower_limit="0.78" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seropositive Memory Response (in Step 3)</title>
        <description>Seropositive memory response was defined for each serogroup by having protective antibody levels (titer &gt;= 1:128) on Day 0 or change from seronegative to seropositive between booster dose (Day 0) and Day 7.</description>
        <time_frame>Step 3 entry and Week 1 post-booster vaccine</time_frame>
        <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seropositive Memory Response (in Step 3)</title>
          <description>Seropositive memory response was defined for each serogroup by having protective antibody levels (titer &gt;= 1:128) on Day 0 or change from seronegative to seropositive between booster dose (Day 0) and Day 7.</description>
          <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive memory responder, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="0.80" upper_limit="0.95"/>
                    <measurement group_id="O2" value="61" lower_limit="0.83" upper_limit="0.98"/>
                    <measurement group_id="O3" value="35" lower_limit="0.85" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive memory responder, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="0.75" upper_limit="0.92"/>
                    <measurement group_id="O2" value="55" lower_limit="0.71" upper_limit="0.90"/>
                    <measurement group_id="O3" value="34" lower_limit="0.81" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive memory responder, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="0.80" upper_limit="0.95"/>
                    <measurement group_id="O2" value="60" lower_limit="0.80" upper_limit="0.96"/>
                    <measurement group_id="O3" value="34" lower_limit="0.81" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive memory responder, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="0.83" upper_limit="0.97"/>
                    <measurement group_id="O2" value="57" lower_limit="0.74" upper_limit="0.93"/>
                    <measurement group_id="O3" value="33" lower_limit="0.78" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Primary Response (in Step 3)</title>
        <description>Primary response was defined for each serogroup as a four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; OR a change from seronegative on day 0 to seropositive on day 28, but not between day 0 and day 7. Note: a primary response can only occur in the absence of any memory response.</description>
        <time_frame>Step 3 entry and Week 4 post-booster vaccine</time_frame>
        <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants aged 11 to 24 with a CD4 percentage of or greater than 15%, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Response (in Step 3)</title>
          <description>Primary response was defined for each serogroup as a four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; OR a change from seronegative on day 0 to seropositive on day 28, but not between day 0 and day 7. Note: a primary response can only occur in the absence of any memory response.</description>
          <population>Because response is a combination of memory and primary response, only participants with data for weeks 0, 1 and 4 are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary responder, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="0.10"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0.10"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary responder, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="0.07"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0.08"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary responder, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.05"/>
                    <measurement group_id="O3" value="2" lower_limit="0.01" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary responder, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="0.07"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0.11"/>
                    <measurement group_id="O3" value="2" lower_limit="0.01" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenic Response to Serogroup C in Group 2</title>
        <description>Immunogenic response as assessed by number of participants with protective antibody titers (&gt;= 1:128) to serogroup C in Group 2 (entry CD4%&lt;15)</description>
        <time_frame>At Weeks 4, 28, and 72</time_frame>
        <population>Group 2 participants with response data for weeks 4, 28 and 72</population>
        <group_list>
          <group group_id="O1">
            <title>Week 4</title>
            <description>Group 2 participants at Week 4</description>
          </group>
          <group group_id="O2">
            <title>Week 28</title>
            <description>Group 2 participants at Week 28 (4 weeks after second vaccination)</description>
          </group>
          <group group_id="O3">
            <title>Week 72</title>
            <description>Group 2 participants at Week 72</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenic Response to Serogroup C in Group 2</title>
          <description>Immunogenic response as assessed by number of participants with protective antibody titers (&gt;= 1:128) to serogroup C in Group 2 (entry CD4%&lt;15)</description>
          <population>Group 2 participants with response data for weeks 4, 28 and 72</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protective Antibody Titers for Serogroup C at Step 3 Entry</title>
        <description>Number of participants with protective antibody titers (rSBA&gt;=1:128) for serogroup C by treatment arm (1 vs. 2 doses) of Group 1 (entry CD4% &gt;= 15) at Step 3 entry</description>
        <time_frame>At 3.5 years</time_frame>
        <population>Group 1 and 3 participants at entry to Step 3</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Age 2-&lt;6</title>
            <description>Participants 2 to &lt;6 years with CD4%&gt;=25</description>
          </group>
          <group group_id="O4">
            <title>Group 3: Age 6-&lt;11</title>
            <description>Participants 6 to &lt;11 years with CD4%&gt;=25</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protective Antibody Titers for Serogroup C at Step 3 Entry</title>
          <description>Number of participants with protective antibody titers (rSBA&gt;=1:128) for serogroup C by treatment arm (1 vs. 2 doses) of Group 1 (entry CD4% &gt;= 15) at Step 3 entry</description>
          <population>Group 1 and 3 participants at entry to Step 3</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Memory for Serogroup C by Treatment Arm (1 vs. 2 Doses)</title>
        <description>Evidence of immunologic memory according to each of the following definitions:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.</description>
        <time_frame>At Week 1 post-booster vaccination</time_frame>
        <population>Participants in Group 1 who entered Step 3</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Memory for Serogroup C by Treatment Arm (1 vs. 2 Doses)</title>
          <description>Evidence of immunologic memory according to each of the following definitions:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.</description>
          <population>Participants in Group 1 who entered Step 3</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunologic Memory or Primary Response for Serogroup C by Treatment Arm</title>
        <description>Immunologic Memory defined as:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.
Primary Response defined as:
A four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; or
A change from titer &lt;1:128 on day 0 to titer â‰¥1:128on day 28, but not between day 0 and day 7.</description>
        <time_frame>At Week 4 post-booster vaccination</time_frame>
        <population>Group 1 participants who entered Step 3</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Memory or Primary Response for Serogroup C by Treatment Arm</title>
          <description>Immunologic Memory defined as:
Secondary (anamnestic) response defined as a four-fold rise in Ab titers between day 0 (booster dose) and day 7; or
Seroprotection on day 0 or change from titer &lt;1:128 to titer â‰¥1:128 (seroprotection) between day 0 and day 7.
Primary Response defined as:
A four-fold rise in Ab concentration between day 0 and day 28, but not between day 0 and day 7; or
A change from titer &lt;1:128 on day 0 to titer â‰¥1:128on day 28, but not between day 0 and day 7.</description>
          <population>Group 1 participants who entered Step 3</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety, as Assessed by Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Step 3 Dose of the Vaccine.</title>
        <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
        <time_frame>From administration of vaccination at Step 3 entry through 6 weeks post-vaccination</time_frame>
        <population>All participants who were vaccinated at Step 3 entry</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants â‰¤11 to &lt;25 years of age with CD4% at screening â‰¥15%</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Participants &gt;=2 to &lt;11 years of age with CD4% at screening â‰¥ 25%</description>
          </group>
        </group_list>
        <measure>
          <title>Safety, as Assessed by Number of Participants With Reactions and Grade 3 or Higher Adverse Events Within 42 Days Following Step 3 Dose of the Vaccine.</title>
          <description>Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009, which is available on the RSC web site (http://rsc.tech-res.com/safetyandpharmacovigilance/). Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = death.</description>
          <population>All participants who were vaccinated at Step 3 entry</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immunogenicity at Step 3 Weeks 4 and 24</title>
        <description>Immunogenicity was assessed by the number of participants with protective levels of antibody (titers greater than or equal to 1:128)</description>
        <time_frame>At Step 3 Weeks 4 and 24 post-booster vaccine</time_frame>
        <population>Participants with data for Step 3 weeks 4 and 24. The numbers for Group 1 (1-dose), Group 1 (2-dose), and Group 3 respectively are:
Week 4: 73, 71, 37 Week 24: 73, 70, 33</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1A</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 1 dose MCV4 vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 1B</title>
            <description>Participants â‰¥11 to &lt;25 years with CD4%&gt;15, 2 doses MCV4 vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25, 2 doses MCV4 vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immunogenicity at Step 3 Weeks 4 and 24</title>
          <description>Immunogenicity was assessed by the number of participants with protective levels of antibody (titers greater than or equal to 1:128)</description>
          <population>Participants with data for Step 3 weeks 4 and 24. The numbers for Group 1 (1-dose), Group 1 (2-dose), and Group 3 respectively are:
Week 4: 73, 71, 37 Week 24: 73, 70, 33</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 immunogenicity, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="0.81" upper_limit="0.96"/>
                    <measurement group_id="O2" value="67" lower_limit="0.86" upper_limit="0.98"/>
                    <measurement group_id="O3" value="37" lower_limit="0.86" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 immunogenicity, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="0.73" upper_limit="0.91"/>
                    <measurement group_id="O2" value="60" lower_limit="0.77" upper_limit="0.94"/>
                    <measurement group_id="O3" value="35" lower_limit="0.78" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 immunogenicity, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="0.83" upper_limit="0.97"/>
                    <measurement group_id="O2" value="64" lower_limit="0.82" upper_limit="0.97"/>
                    <measurement group_id="O3" value="37" lower_limit="0.86" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 immunogenicity, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="0.83" upper_limit="0.97"/>
                    <measurement group_id="O2" value="62" lower_limit="0.78" upper_limit="0.95"/>
                    <measurement group_id="O3" value="35" lower_limit="0.78" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 immunogenicity, serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="0.70" upper_limit="0.89"/>
                    <measurement group_id="O2" value="59" lower_limit="0.73" upper_limit="0.92"/>
                    <measurement group_id="O3" value="30" lower_limit="0.75" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 immunogenicity, serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="0.44" upper_limit="0.68"/>
                    <measurement group_id="O2" value="46" lower_limit="0.52" upper_limit="0.76"/>
                    <measurement group_id="O3" value="24" lower_limit="0.53" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 immunogenicity, serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="0.67" upper_limit="0.87"/>
                    <measurement group_id="O2" value="53" lower_limit="0.63" upper_limit="0.85"/>
                    <measurement group_id="O3" value="32" lower_limit="0.84" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 immunogenicity, serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="0.68" upper_limit="0.88"/>
                    <measurement group_id="O2" value="52" lower_limit="0.61" upper_limit="0.84"/>
                    <measurement group_id="O3" value="31" lower_limit="0.79" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry through Step 3, week 24 (4 years )</time_frame>
      <desc>All vaccine-related Grade â‰¥ 3 toxicities, and any new Grade 2 or higher neuromuscular weakness occurring within 42 days of vaccination were reported. Adverse events were graded by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004, Clarification August 2009.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (15&lt;CD4%â‰¤25)</title>
          <description>Participants â‰¥11 to &lt;25 years with 15&lt;CD4%â‰¤25</description>
        </group>
        <group group_id="E2">
          <title>Group 1 (CD4%â‰¥25)</title>
          <description>Participants â‰¥11 to &lt;25 years with CD4%â‰¥25</description>
        </group>
        <group group_id="E3">
          <title>Group 2</title>
          <description>Participants â‰¥11 to &lt;25 years with CD4%&lt;15</description>
        </group>
        <group group_id="E4">
          <title>Group 3</title>
          <description>Participants â‰¥ 2 to &lt;11 years with CD4% â‰¥25</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

